https://www.pharmnovo.com/post/the-clinical-trial-application-cta-has-been-submitted

THE CTA IS SUBMITTED

May 30, 2022

PharmNovo is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as to the ethics committee for a phase I First in Human (FIH) clinical trial with our lead candidate PN6047.

The FIH trial will be conducted at the Swedish CRO Clinical Trial Consultants AB (CTC) at their FIH facility in Uppsala. It is planned to enrol approximately 100 healthy subjects into the trial.

The CTA submission is the culmination of several years of dedicated CMC- and preclinical work creating documentation that the compound is safe for human testing, and the submission of the CTA for the FIH clinical trial represent a major milestone in the development of PN6047.

Latest news

View all
June 3, 2022

67 MSEK IN NEW FUNDING

We are pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety.

May 30, 2022

THE CTA IS SUBMITTED

The Clinical Trial Application (CTA) has been submitted to the MPA

November 18, 2021

CTC AWARDED AS CRO

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

October 29, 2021

CANADA PATENT GRANT

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

← Back
No items found.
May 30, 2022

THE CTA IS SUBMITTED

PharmNovo is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as to the ethics committee for a phase I First in Human (FIH) clinical trial with our lead candidate PN6047.

The FIH trial will be conducted at the Swedish CRO Clinical Trial Consultants AB (CTC) at their FIH facility in Uppsala. It is planned to enrol approximately 100 healthy subjects into the trial.

The CTA submission is the culmination of several years of dedicated CMC- and preclinical work creating documentation that the compound is safe for human testing, and the submission of the CTA for the FIH clinical trial represent a major milestone in the development of PN6047.

May 30, 2022

THE CTA IS SUBMITTED

PharmNovo is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as to the ethics committee for a phase I First in Human (FIH) clinical trial with our lead candidate PN6047.

The FIH trial will be conducted at the Swedish CRO Clinical Trial Consultants AB (CTC) at their FIH facility in Uppsala. It is planned to enrol approximately 100 healthy subjects into the trial.

The CTA submission is the culmination of several years of dedicated CMC- and preclinical work creating documentation that the compound is safe for human testing, and the submission of the CTA for the FIH clinical trial represent a major milestone in the development of PN6047.

Author:

Petra Larson

Author:

Petra Larson

67 MSEK IN NEW FUNDING

We are pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety.

Read more →

CTC AWARDED AS CRO

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

Read more →

CANADA PATENT GRANT

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

Read more →

MEET OUR CMO

PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map